BioMed Realty Trust, Inc. (NYSE: BMR) said Oct. 8 that private equity firm Blackstone Group L.P. has agreed to acquire the life sciences office and lab space REIT in an all-cash transaction valued at $ 8 billion.
Blackstone’s real estate arm, Blackstone Real Estate Partners VIII, will pay $ 23.75 for each outstanding BioMed common share. This represents a premium of about 24 percent above the closing stock price on Sept. 22, the last date before speculation began about a potential sale of the company.